COMPREHENSIVE BIOMARKER AND GENOMIC ANALYSIS IDENTIFIES P53 STATUS AS THE MAJOR DETERMINANT OF RESPONSE TO MDM2 INHIBITORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
The results of these studies conclusively demonstrate that p53 status is the major determinant of response to MDM2 inhibitors in CLL. Additional defects in the p53 regulatory cascade do not appear operational in this leukemia.
Further, we identify a novel subgroup of CLL patients with early progressive disease that appears particularly sensitive to MDM2 inhibitor treatment.
These data provide definitive evidence for target-specific and predictive activity and a rationale to proceed with this potentially important class of compounds in the treatment of CLL.
only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western world, and is characterized by a highly variable clinical course 1, 2 . Treatment of CLL is reserved for symptomatic patients or patients in advanced clinical stage.
Despite improvements in response rates using chemoimmunotherapy combinations, CLL remains incurable, and patients refractory to fludarabine or patients that have suffered multiple disease relapses have a poor outlook [3] [4] [5] . Therefore, novel therapeutics are needed to advance the outlook for afflicted patients.
Inhibitors of murine double minute (Mdm) 2 represent a novel therapeutic approach [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In cells with functional p53, the p53 activity is primarily inhibited through direct and tonic interaction with the MDM2 protein [20] [21] [22] . Treatment of various tumor cells with inhibitors of the MDM2-p53 interaction results in rising p53 levels and subsequent induction of cell cycle arrest and apoptosis. For poorly understood reasons, non-malignant cells appear relatively resistant to MDM2 inhibition 23, 24 .
In CLL, in contrast to many solid tumors, p53 is mutated in only about 10% of patients at presentation and in 10-30% of patients with pre-treated disease [25] [26] [27] [28] .
Thus, small-molecule inhibitors that block the MDM2-p53 interaction could represent a new therapeutic strategy for the treatment of most CLL patients.
Human cancers are biologically heterogeneous and respond non-uniformly to therapeutic intervention. Therefore, understanding the molecular mechanisms only.
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CLL is heterogeneous and several disease-related factors have been identified that classify CLL into biologically distinct and clinically relevant subtypes. Investigation into these subtypes has revealed clues about mechanisms of disease and patient prognosis 2, 29, 30 . Lack of mutation in the immunoglobulin heavy-chain variable region (IgV H ) genes, increased expression of zeta-associated protein of 70kDa (ZAP-70) and mutations involving p53 and/or ATM genes are some of the molecular parameters which have been associated with an aggressive disease course, shortened disease-free intervals, and compromised survival 28, [31] [32] [33] [34] [35] [36] [37] [38] [39] . Importantly, interphase fluorescent in-situ hybridization (FISH) has identified chromosomal changes in approximately 80% of patients with CLL, and the presence of select chromosomal abnormalities, such as del(17p), has proven to be a prognostic indicator for response to therapy, disease progression after therapy and survival 29, 40, 41 .
Given that loss of p53 or genes important for p53-induced apoptosis may confer resistance to therapies, including MDM2 inhibitors, we compared data from in-vitro treatments of tumor cells from over 100 CLL patients with two MDM2-inhibiting compounds to patient-specific, unbiased, genome-wide copy number analyses using high-density SNP arrays and measurements of clinically relevant biomarkers [42] [43] [44] [45] [46] [47] . . Eligible patients needed to have an absolute lymphocytosis (greater than 5000 mature lymphocytes per µl), and lymphocytes needed to express CD19, CD23, sIg (weak) and CD5 in the absence of pan-T-cell markers. Five patients enrolled on the study were excluded from analysis (diagnoses: large cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, Crohn's disease and CLL with concurrent AML). Three post-treatment patient samples gave insufficient DNA for analysis and thus were excluded from analysis.
Of these 179 patients, samples from 171 cases were used for this study.
For MDM2 inhibitor kill assays, 106 cases were selected to represent various CLL subtypes and were enriched for known p53 abnormalities. Eighty-five cases were previously untreated and twenty-one previously treated (Supplementary Table 1 ). The 85 untreated cases were previously analyzed for CLL biomarkers and genomic complexity as described 49 .
CLL treatment was defined as cytotoxic chemotherapy and/or monoclonal antibody therapy for CLL and/or associated autoimmune cytopenias. 
Cell Isolation

Cell Purification
Peripheral blood mononuclear cells from CLL patients were isolated by Ficoll gradient centrifugation (GE Healthcare), aliquoted into FCS with 10% DMSO, and cryopreserved in liquid nitrogen.
Flow Cytometry
Cryopreserved CLL cells were washed and stained with phycoerythrinconjugated anti-CD19 and FITC-conjugated anti-CD3 antibodies (eBioscience). 
Array Data Analysis
Affymetrix data files were generated from SNP chips post-hybridization via scanners at the U. Time to first treatment (TTFT) was the sole clinical endpoint that we used.
The Kaplan-Meier method was used to estimate the survivor function to first treatment for each subgroup (CLL cases with and without aberrant p53 induction by immunoblotting), and the log-rank test was used to calculate p-values to test for significant differences in the survivor function between subgroups.
Assessments of the relationship between MDM2 inhibitor ex vivo IC50 kill values and clinical outcome.
Cox proportional hazards models were used to assess univariate associations between time to first treatment (TTFT) and the IC50 value for p53 wild type samples. In these models, TTFT is related to a linear predictor of the form b*IC50. The fitted coefficient b means that given two subjects that are untreated at a fixed time T after study entry, and that differ one unit in IC50, the subject with higher IC50 has approximately exp(b) times greater risk of going only. 
Mutation Status
PCR was used to amplify IgV H regions using CLL sample CD19+ sorted cell-derived genomic DNA or cDNA as templates. Trizol was used to purify total RNA, and the Superscript III first-strand RT-PCR kit was used to generate first strand cDNA (random primed, Invitrogen). Primers were a mixture of seven FR1-primers using the BIOMED2 consortium primers and the modified J-consensus primer 5'-ACCTGAGGAGACGGTGACCAGGGT-3' (Jc) 52 . Amplifications were done using Platinum-PFX (Invitrogen) and optimized using gradient PCR conditions. Products were fractionated on 2% agarose gels, excised and eluted using the Qiaquick gel extraction kit and directly sequenced using primer Jc.
Products were also cloned using the Zero Blunt Topo PCR cloning kit (PCR Blunt II topo vector, Invitrogen) and multiple clones per patient sequenced using M13 primers. Sequences were compared against the IgV H -database using the NCBI Ig-Blast search engine (http://www.ncbi.nlm.nih.gov/igblast/). 98% homology to germline was used as a cut-off for unmutated status assignment. 
p53 Genomic DNA Sequencing
Primers to amplify exons 5/6, 7 and 8/9 of human p53 and adjacent intronic sequences were designed using the primer 3 program. The sequence of the primers used is as follows: p53-E5/6-F: 5'-ggaggtgcttacgcatgtttt, p53-E5/6-R:
5'-gggaggtcaaataagcagca, p53-E7-F: 5'-aaaaaggcctcccctgct, p53-E7-R: 5'-tggaagaaatcggtaagaggtg, p53-E8/9-F: caagggtggttgggagtaga, p53-E8/9-R: ccccaattgcaggtaaaaca. PCR products were generated using DNA templates from FACS-sorted CD19+ or CD3+ cells. Amplifications were done using Taq only.
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Fluorescence in Situ Hybridization
Fluorescence in situ hybridization (FISH) was performed for patient MI-63 and MI-61 were synthesized using previously published methods 15, 16 . Nutlin3 was provided by Dr. Wang. We have previously reported that MI-63 binds to MDM2 with a K i value of 3nM. MI-61 is a close homologue of MI-63 and binds MDM2 with >3000-fold lower affinity, and was thus used as an inactive control in this study. 
RESULTS
Patient Characteristics
Included in this study are samples and clinical data from 171 patients with CLL that are enrolled in an ongoing prospective CLL profiling study.
Characteristics for 106 patients that were analyzed for MDM2 inhibitor-mediated cell kill are summarized in Table 1 and detailed in Supplementary Table 1 .
Eighty-five (80%) patients were previously untreated, and twenty-one (20%) patients were pretreated with either alkylator-or purine analogue-based inhibition in CLL, we defined 171 CLL patients for p53 allele status, p53 LOH and p53 mutations. We analyzed genomic profiles of CLL patients using the Affymetrix 50kSNP platform, clinical FISH data using a probe spanning the p53 locus and p53 sequence data for exons 5-9. only.
For Fig.1A , LOH analysis (buccal DNA versus CD19+ CLL cells) for chromosome 17p for all SNPs and for all patients is shown. Through comparison of LOH calls (Fig.1A) with clinical FISH data (Fig.1B) , we noted that 3 patients (CLL#33, 53 and 143) were not previously known to carry abnormalities at 17p.
We therefore analyzed copy number estimates for 17p for all patients and found that CLL#33 and #53 (Fig. 1C, red) had a normal 2N state at 17p while #143 demonstrated del17p (1N). Therefore, copy neutral LOH (uniparental disomy) exists at 17p (CLL #33 and 53) and would escape detection using the clinically important FISH assay.
It is commonly assumed that the del17p indicates that p53 is mutated on the retained allele. We decided to test this relationship through comparison of dChipSNP-based copy number estimates for 17p, FISH data and p53 mutation status.
As can be seen in Fig. 1C&D, 3 out of 15 patients (CLL#14, 74 and 84 in green) with copy loss at 17p had no p53 mutations in the retained allele. The two patients with LOH but no 17p copy loss (CLL#33 and #53 in red) had either a polymorphism in the germline (CD3+ cells as template) that encoded for an amino acid change (CLL#33 with either p53 R248 and Q248 in the germline) that converted to Q248 in the CLL cells, or a homozygous mutation (CLL#53).
CLL#16, 92, 151 and 176 (Fig.1C in blue) , which had neither LOH nor copy loss at 17p, carried p53 mutations.
Finally, multiple CLL cases (Fig. 1A&C in black) , with both LOH and copy loss at 17p, carried p53 mutations on the remaining allele.
P53 protein levels in CLL samples at baseline and in response to MDM2 inhibitors:
To corroborate p53 sequence data and to detect additional p53 aberrations, we measured p53 levels pre-and post-MDM2 inhibitor treatment by immunoblotting in purified CD19+ tumor cells from all 106 studied CLL cases.
As expected, p53 levels were elevated post-MDM2 inhibitor treatment in all samples with wt p53 status when compared with either untreated cells or cells treated with the inactive compound MI-61 (see Fig.2A for representative samples). P53 levels were high and were not further induced in samples with known p53 point mutations (Fig.2B for representative samples) .
Aberrant short p53 protein was detected in 2 cases (Fig.2C ) and was associated with relative resistance to MDM2 inhibitor treatment.
Finally, we detected 3 CLL cases with essentially absent p53 levels that were unchanged by MDM2 inhibitor treatment (Fig.2D) . All three cases carried monoallelic del17p. These cases displayed relative resistance to MDM2 inhibitor treatment, comparable to p53 sequence mutants as described below.
Measurements of MDM2 inhibitor-mediated cell kill in a large CLL cohort
Highly purified CD19+ cells (see material and methods section) from 106 CLL patients were incubated with two different MDM-2 inhibitors (MI-63 and Nutlin3) at the indicated concentrations (Fig. 3A&B ) for ~36 hours, and apoptotic (Annexin-V-staining) and necrotic (PI-staining) cell death was measured using Only a few CLL cases with wt p53 status and wt p53 induction by immunoblotting in response to MDM2 inhibition displayed resistance to MDM2 inhibitor treatment that was comparable to the known p53 mutant cases (Fig.3A&B) . Therefore, p53 status emerged as the major determinant of responsiveness to MDM2 inhibitors in CLL. 
The influence of established clinically important biomarkers on response to
MDM2 inhibitors in CLL
We also assessed whether the presence or absence of unfavorable biomarkers used clinically in CLL, including unmutated immunoglobulin variable genes (IgV H -unmutated), expression of ZAP-70 or presence of select FISH findings, predicted for MDM2 treatment response (Fig.5A-F) .
As can be seen in 
DISCUSSION
This study examines the efficacy of in vitro MDM2 inhibitor-mediated cell kill of purified primary CLL tumor cells in a large cohort of CLL patients for whom comprehensive clinical risk data is available and for which high-quality genomewide sub-chromosomal copy number and LOH data have been accumulated. From this it has been possible to firmly conclude that p53 status is the major determinant of responsiveness to MDM2 inhibitor treatment in CLL.
This conclusion applies to treatment naïve as well as chemotherapy pretreated CLL. Defects in the p53 regulatory network, including defects in p53-induced apoptotic effector molecules, do not appear to play a significant role in CLL response to MDM2 inhibition [53] [54] [55] [56] [57] [58] . This is in concordance with three previous reports of pilot studies [59] [60] [61] .
MDM2 inhibitors therefore potentially offer efficacious cancer cell killing for the majority of CLL patients with high-risk or relapsed disease.
Our integrated genomic profiling analysis of chromosome arm 17p together with p53 sequence data and p53 immunoblotting supports the conclusion that all del17p cases (by FISH) have aberrant p53 function; given that four cases of p53 mutants/absent expression without del17p were identified (including 2 cases with copy-neutral LOH at 17p and homozygous p53 mutations) that demonstrated resistance to MDM2 inhibition, we conclude that CLL patients with del17p are resistant to MDM2 inhibition secondary to associated p53 abnormalities. Therefore, the clinically important del17p subgroup only.
For We also conclude that p53 immunoblotting pre-and post-MDM2 inhibitor treatment more comprehensively interrogates p53 defects than either FISH for del17p or p53 exon resequencing 62 .
During these studies we identified for the first time a strong correlation between high sensitivity to MDM2 inhibitor cell kill ex vivo and aggressive CLL in cases with wild type p53 function. This is a novel finding and potentially of significant clinical importance, as these patients with early need for therapy may benefit from MDM2 inhibitor therapy.
As previously reported in a small patient sampling, ZAP-70 expression or mono-allelic ATM loss did not affect MDM2 inhibitor susceptibility 59 . We confirm and extend this observation using our larger patient cohort. Furthermore, we report that the mutation status of the IgV H genes does not predict MDM2 inhibitor mediated cell kill in CLL. 
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